Sinovac GAAP net loss widens to $60.2 million in 1H FY26; sales rise 12.9% to $147.1 million

Reuters2026/08/17 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sinovac posted H1 2026 sales of USD 147.1 million, up 12.9% from the prior-year period.
Net loss attributable to common shareholders widened to USD 60.2 million, or USD 0.84 per share.
Gross profit rose to USD 95.5 million; gross margin improved 2.5 percentage points to 65%.
Overseas revenue more than doubled to USD 66.5 million, up 82.3%, representing 45.2% of total sales.
CEO Weidong Yin said the rabies vaccine PVRV-SF won NMPA approval on Aug. 4, 2026; WHO PQ filing planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260817205963) on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sinovac GAAP net loss widens to $60.2 million in 1H FY26; sales rise 12.9% to $147.1 million

You may also like

Crypto prices